Volitionrx Ltd (VNRX)
Official siteHEALTHCARE • MEDICAL DEVICES • AMEX
Market Cap: $7.21M
Last updated: Nov 17, 2026 at 4:30 PM ET
Volitionrx Ltd (VNRX) Statistics
Volitionrx (VNRX) has a market cap of $7.21M and an enterprise value of $12.78M. It kept -700.48% of revenue as net income over the last 12 months. Revenue grew 133.54% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 77.25% above the market cap, as debt exceeds cash.
| Market Cap | $7.21M |
|---|---|
| Enterprise Value | $12.78M |
| Latest price (Nov 17, 2026) | $0.18 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 1.9x. Its year-end P/S ranged from 19.4x to 440.7x from 2022 to 2025.
| P/S Ratio | 1.9x |
|---|---|
| Forward P/S | 2.6x |
Price Statistics
The stock is down 97.21% over 52 weeks and trades 18.18% below its 50-day average.
| Beta (1Y) | 1.46 |
|---|---|
| 52-Week Change | -97.21% |
| 1-Month Change | +6.16% |
| 3-Month Change | -62.20% |
| 6-Month Change | -92.15% |
| 5-Year Change | -99.71% |
| 10-Year Change | -99.78% |
| Total Return (1Y) | -97.21% |
| Total Return (3Y CAGR) | -76.89% |
| Total Return (5Y CAGR) | -70.22% |
| Max Drawdown (1Y) | -97.66% |
| Max Drawdown (3Y) | -99.30% |
| Sharpe Ratio (1Y) | -3.42 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $0.22 |
| 200-Day Average | $1.84 |
| 52-Week Range | $0.16 to $7.73 |
| RSI (14 Days) | 43.9 |
| Average Volume (20 Days) | 4.08M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.33x current liabilities.
| Current Ratio | 0.33x |
|---|---|
| Quick Ratio | 0.33x |
| Interest Coverage | -3.96x |
Returns and Efficiency
Return on invested capital is 83.67% over the last 12 months.
| Return on Assets (ROA) | -334.96% |
|---|---|
| Return on Invested Capital (ROIC) | 83.67% |
| Asset Turnover | 0.50x |
| Receivables Turnover | 14.98x |
Scores
VNRX has an Altman Z-Score of -62.06, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -62.06 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $3.44M over the last 12 months.
| Revenue | $3.44M |
|---|---|
| Revenue Growth (YoY) | +133.54% |
| Gross Profit | $3.44M |
| Operating Income | -$17.66M |
| Pretax Income | -$24.13M |
| Net Income | -$24.13M |
| EBITDA | -$16.11M |
| EBIT | -$19.27M |
| Reported EPS (TTM) | -$2.00 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $2.36M |
|---|---|
| Total Debt | $7.93M |
| Net Debt | $5.57M |
| Net Debt Per Share | $0.15 |
| Working Capital | -$6.66M |
| Shareholder Equity | -$26.12M |
| Tangible Book Value | -$26.41M |
| Total Assets | $7.20M |
| Total Liabilities | $34.70M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $68.91K of capital spending, operating cash flow left -$20.59M of free cash flow.
| Operating Cash Flow | -$20.52M |
|---|---|
| Capital Expenditures | $68.91K |
| Free Cash Flow | -$20.59M |
| FCF Per Share | -$0.68 |
| Depreciation and Amortization | $3.16M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -512.59%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -512.59% |
| Pretax Margin | -700.54% |
| Net Margin | -700.48% |
| EBITDA Margin | -467.59% |
| EBIT Margin | -559.29% |
| FCF Margin | -597.63% |
Growth
Revenue grew 77.98% a year over 3 years.
| Revenue Growth (3Y CAGR) | +77.98% |
|---|---|
| Revenue Growth (5Y CAGR) | +129.95% |
Dividends and Yields
VNRX does not pay a dividend. Its free cash flow yield is -309.23%.
| FCF Yield | -309.23% |
|---|---|
| Buyback Yield | -364.24% |
| Shareholder Yield | -364.24% |
Stock Splits
The last split was a 1-for-20 reverse split on Apr 28, 2026.
| Last Split Date | Apr 28, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 7 similar companies, VNRX has the 2nd highest P/S.
P/S RatioPeer median 0.6x
ROICPeer median -147.05%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.79%
| P/S Ratio | 1.9x vs 0.6x median |
|---|---|
| ROIC | 83.67% vs -147.05% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +133.54% vs +7.79% median |
Analyst Forecast
Consensus estimates put revenue growth at 131.71% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +131.71% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About VNRX
What is VNRX's market cap?
Volitionrx has a market cap of $7.21M. Its enterprise value, which adds debt and subtracts cash, is $12.78M.
How many shares of VNRX are outstanding?
Volitionrx has 36.08M shares outstanding.
Does VNRX pay a dividend?
No. Volitionrx does not pay a dividend.
How much debt does VNRX have?
Volitionrx has $7.93M of total debt and $2.36M of cash and equivalents, a net debt position of $5.57M.
VNRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors